Welcome to our dedicated page for CHINA INFRASTRUCTURE CONSTRUCTI news (Ticker: CHNC), a resource for investors and traders seeking the latest updates and insights on CHINA INFRASTRUCTURE CONSTRUCTI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CHINA INFRASTRUCTURE CONSTRUCTI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CHINA INFRASTRUCTURE CONSTRUCTI's position in the market.
CBIH, formerly known as CHNC, has announced a significant rebranding effort to enhance its identity and reflect its commitment to medical advancements. The rebranding includes a new logo and aims to better communicate the company's focus and vision for the future. The transition will involve updating all digital content and marketing materials, with plans to complete this by the end of July 2023. CBIH's management emphasizes that this change will not disrupt ongoing relationships with educational and pharmaceutical partners. The rebrand is intended to clarify the company’s operations in clinical trials, sleep studies, and cannabis education from its Houston, Texas office.
CBIH, formerly known as CHNC, has appointed former NFL player David Irving as its new spokesperson. Irving, a notable advocate for cannabis use in sports, gained attention for pushing to reform outdated NFL drug policies after his own suspension for a positive drug test. He highlights the medical benefits of cannabis for anxiety, pain management, and sleep issues, advocating against the stigma and promoting awareness of its potential benefits compared to traditional opioid treatments. CBIH's leadership believes that Irving's experience and commitment will enhance the company's mission of advancing science and education in the cannabis field.
China Infrastructure Construction Corp. (CHNC) announced the completion of its public audit on March 21, 2022, and the review of its financial statements for the first three quarters of the fiscal year ending May 31, 2022. The company aims to change its corporate name to Cannabis Bioscience International Holdings, Inc., aligning with its cannabis-related activities. CHNC plans to enhance transparency and credibility, potentially moving to the OTCQB tier. The company's VP highlighted its commitment to high standards, striving to stand out in the OTC market.
China Infrastructure Construction Corp (OTC: CHNC) announced the surrender of over 500 million shares by CEO Dante Picazo. These shares will be redistributed to enhance employee benefits through stock options and other compensation plans without causing shareholder dilution. Treasurer Henry Levinski highlighted the initiative's purpose to reward employees for their contributions. The company recently completed an audit of its financial statements and plans to change its corporate name, positioning itself for future challenges.
China Infrastructure Construction Corp (OTC: CHNC) has published its audited financial statements for the fiscal year ending May 31, 2021, conducted by PWR CPA, enhancing its credibility with investors. CEO Dante Picazo hailed this completion as a milestone, with plans to change the company's name to Cannabis Bioscience International Holdings to better reflect its core business. The firm has raised approximately $1.5 million through private placements, aiming to further capitalize on its financial statements. It seeks to venture into the cannabis education market and will become an SEC reporting company.
China Infrastructure Construction Corp (OTC: CHNC) highlights the progress of its clinical trials at Alpha Research Institute in Houston. Currently, Alpha operates 15 clinical trials focusing on various health issues including cancer, diabetes, and COVID-19. The team aims to expand its offerings by recruiting more staff and establishing new sponsor partnerships. The report emphasizes the commitment to patient safety and adherence to FDA guidelines while fostering community relationships. CEO Dante Picazo expresses gratitude to shareholders and staff for their contributions to the company’s growth.
China Infrastructure Construction Corp (OTC: CHNC) has announced an expansion of its educational initiatives through a partnership with Jorge Tadeo Lozano University in Santa Marta, Colombia. This collaboration aims to enhance academic opportunities in the medical cannabis sector, featuring diploma courses with a focus on cultivation practices. Starting in 2022, the program includes 110 hours of virtual and on-site classes, leveraging Santa Marta's strategic location for industry growth. This move is expected to bolster CHNC's leadership in the medical cannabis educational market.
China Infrastructure Construction Corp (OTC:CHNC) has severed ties with its previous PCAOB accounting firm, securing a full refund of all payments. The company has partnered with a new Houston-based firm, Vine Advisors/PWR CPA, to provide timely PCAOB audited financials within 30 to 45 days. Treasurer Henry Levinski expressed optimism about submitting a registration and name change before 2021 ends. CHNC aims to enhance its market presence through a smooth advertising campaign across 32 platforms globally, targeting significant growth in the cannabis education market, projected to reach $75 billion by 2025.
HOUSTON, TX, Nov. 05, 2021 -- CHNC announces a collaboration with Drs. Nada Al-Rubaiee as their new brand ambassador. Dr. Al-Rubaiee is recognized for her credentials in Bio-pharmaceutical sciences and Health Administration, aiming to enhance CHNC's educational outreach in the medicinal cannabis sector. The partnership seeks to develop international alliances with academic institutions, capitalizing on the growing medicinal cannabis market, especially in regions shifting towards legalization, such as Lebanon. Predictions estimate medicinal cannabis sales could reach $90.4 billion globally by 2026.
FAQ